Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rubius Therapeutics, Inc. (RUBY) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rubius Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1709401.
Total stock buying since 2018: $7,259,543.
Total stock sales since 2018: $5,739,822.
Total stock option exercises since 2018: $910,059.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 32,544 | $6,765 | 69,813 | $0 |
| 2022 | 30,000 | $43,320 | 17,716 | $83,326 | 49,263 | $0 |
| 2021 | 210,000 | $6,090,000 | 150,441 | $2,373,347 | 25,000 | $192,500 |
| 2020 | 55,000 | $261,423 | 0 | $0 | 5,000 | $23,700 |
| 2019 | 0 | $0 | 236,696 | $3,276,384 | 463,989 | $693,859 |
| 2018 | 37,600 | $864,800 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-02 | 0 | $0 | 22,711 | $4,399 | 0 | $0 |
| 2023-01 | 0 | $0 | 9,833 | $2,366 | 69,813 | $0 |
| 2022-08 | 0 | $0 | 5,737 | $4,589 | 12,500 | $0 |
| 2022-04 | 30,000 | $43,320 | 0 | $0 | 0 | $0 |
| 2022-02 | 0 | $0 | 11,979 | $78,737 | 0 | $0 |
| 2022-01 | 0 | $0 | 0 | $0 | 36,763 | $0 |
| 2021-03 | 210,000 | $6,090,000 | 25,000 | $505,975 | 25,000 | $192,500 |
| 2021-02 | 0 | $0 | 125,441 | $1,867,372 | 0 | $0 |
| 2020-05 | 0 | $0 | 0 | $0 | 5,000 | $23,700 |
| 2020-04 | 40,000 | $203,523 | 0 | $0 | 0 | $0 |
| 2020-03 | 15,000 | $57,900 | 0 | $0 | 0 | $0 |
| 2019-12 | 0 | $0 | 48,000 | $646,896 | 48,000 | $137,760 |
| 2019-10 | 0 | $0 | 7,500 | $63,877 | 7,500 | $1,125 |
| 2019-09 | 0 | $0 | 48,000 | $485,193 | 48,000 | $137,759 |
| 2019-07 | 0 | $0 | 7,500 | $112,050 | 214,646 | $39,447 |
| 2019-06 | 0 | $0 | 48,000 | $673,076 | 48,000 | $137,759 |
| 2019-04 | 0 | $0 | 22,196 | $425,717 | 7,500 | $1,125 |
| 2019-03 | 0 | $0 | 48,000 | $760,128 | 48,000 | $137,760 |
| 2019-01 | 0 | $0 | 7,500 | $109,447 | 42,343 | $101,124 |
| 2018-07 | 37,600 | $864,800 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-24 | Appelhans Dannielle (CEO and President) | Sale | 10,385 | .13 | 1,318 |
| 2023-02-01 | Appelhans Dannielle (CEO and President) | Sale | 3,878 | .25 | 969 |
| 2023-02-01 | Cagnoni Pablo J | Sale | 8,448 | .25 | 2,112 |
| 2023-01-31 | Appelhans Dannielle (CEO and President) | Option Ex | 7,500 | .00 | 0 |
| 2023-01-31 | Turka Laurence A. (Chief Scientific Officer) | Sale | 2,593 | .24 | 622 |
| 2023-01-31 | Turka Laurence A. (Chief Scientific Officer) | Option Ex | 8,625 | .00 | 0 |
| 2023-01-31 | Cagnoni Pablo J | Sale | 7,240 | .24 | 1,744 |
| 2023-01-31 | Cagnoni Pablo J | Option Ex | 25,000 | .00 | 0 |
| 2023-01-29 | Turka Laurence A. (Chief Scientific Officer) | Option Ex | 7,438 | .00 | 0 |
| 2023-01-29 | Cagnoni Pablo J | Option Ex | 21,250 | .00 | 0 |
| 2022-08-10 | Appelhans Dannielle (Chief Operating Officer) | Sale | 5,737 | .80 | 4,589 |
| 2022-08-09 | Appelhans Dannielle (Chief Operating Officer) | Option Ex | 12,500 | .00 | 0 |
| 2022-04-21 | Epstein David R | Buy | 30,000 | 1.44 | 43,320 |
| 2022-02-01 | Turka Laurence A. (Chief Scientific Officer) | Sale | 2,517 | 6.57 | 16,544 |
| 2022-02-01 | Keson-brookes Maiken (CLO & Corp. Secretary) | Sale | 2,732 | 6.57 | 17,957 |
| 2022-02-01 | Cagnoni Pablo J (CEO and President) | Sale | 6,730 | 6.57 | 44,236 |
| 2022-01-29 | Turka Laurence A. (Chief Scientific Officer) | Option Ex | 7,438 | .00 | 0 |
| 2022-01-29 | Keson-brookes Maiken (CLO & Corp. Secretary) | Option Ex | 8,075 | .00 | 0 |
| 2022-01-29 | Cagnoni Pablo J (CEO and President) | Option Ex | 21,250 | .00 | 0 |
| 2021-03-19 | Afeyan Noubar (Director) | Buy | 210,000 | 29.00 | 6,090,000 |
| 2021-03-15 | Keson-brookes Maiken (CLO & Corp. Secretary) | Sale | 25,000 | 20.24 | 505,975 |
| 2021-03-15 | Keson-brookes Maiken (CLO & Corp. Secretary) | Option Ex | 25,000 | 7.70 | 192,500 |
| 2021-02-11 | Epstein David R | Sale | 26,704 | 14.93 | 398,557 |
| 2021-02-10 | Epstein David R | Sale | 7,404 | 14.79 | 109,527 |
| 2021-02-09 | Epstein David R | Sale | 2,100 | 14.83 | 31,145 |
| 2021-02-08 | Epstein David R | Sale | 89,233 | 14.88 | 1,328,143 |
| 2020-05-15 | Oh Andrew M. (Chief Financial Officer) | Option Ex | 5,000 | 4.74 | 23,700 |
| 2020-04-22 | Coughlin Christina M. (Chief Medical Officer) | Buy | 19,000 | 5.52 | 104,823 |
| 2020-04-14 | Cagnoni Pablo J (CEO and President) | Buy | 21,000 | 4.70 | 98,700 |
| 2020-03-17 | Epstein David R (Director) | Buy | 5,000 | 3.76 | 18,800 |
| 2020-03-13 | Epstein David R (Director) | Buy | 10,000 | 3.91 | 39,100 |
| 2019-12-16 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 48,000 | 13.48 | 646,896 |
| 2019-12-16 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 48,000 | 2.87 | 137,760 |
| 2019-10-14 | Langer Robert (Director) | Sale | 7,500 | 8.52 | 63,877 |
| 2019-10-14 | Langer Robert (Director) | Option Ex | 7,500 | .15 | 1,125 |
| 2019-09-17 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 11,877 | 10.04 | 119,304 |
| 2019-09-17 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 11,877 | 2.87 | 34,086 |
| 2019-09-16 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 36,123 | 10.13 | 365,889 |
| 2019-09-16 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 36,123 | 2.87 | 103,673 |
| 2019-07-24 | Nissen Torben Straight (President) | Option Ex | 207,146 | .18 | 38,322 |
| 2019-07-15 | Langer Robert (Director) | Sale | 7,500 | 14.94 | 112,050 |
| 2019-07-15 | Langer Robert (Director) | Option Ex | 7,500 | .15 | 1,125 |
| 2019-06-20 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 243 | 13.93 | 3,385 |
| 2019-06-20 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 243 | 2.87 | 697 |
| 2019-06-19 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 18,399 | 13.80 | 253,869 |
| 2019-06-19 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 18,399 | 2.87 | 52,805 |
| 2019-06-18 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 10,858 | 14.27 | 154,954 |
| 2019-06-18 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 10,858 | 2.87 | 31,162 |
| 2019-06-17 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 18,500 | 14.10 | 260,868 |
| 2019-06-17 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 18,500 | 2.87 | 53,095 |
| 2019-04-15 | Langer Robert (Director) | Sale | 7,500 | 17.57 | 131,797 |
| 2019-04-15 | Langer Robert (Director) | Option Ex | 7,500 | .15 | 1,125 |
| 2019-04-08 | Nissen Torben Straight (President) | Sale | 2,100 | 20.00 | 42,000 |
| 2019-04-05 | Nissen Torben Straight (President) | Sale | 12,096 | 20.00 | 241,920 |
| 2019-04-03 | Nissen Torben Straight (President) | Sale | 500 | 20.00 | 10,000 |
| 2019-03-15 | Carpenter Christopher L. (Chief Medical Officer) | Sale | 48,000 | 15.84 | 760,128 |
| 2019-03-15 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 48,000 | 2.87 | 137,760 |
| 2019-01-22 | Carpenter Christopher L. (Chief Medical Officer) | Option Ex | 34,843 | 2.87 | 99,999 |
| 2019-01-14 | Langer Robert (Director) | Sale | 7,500 | 14.59 | 109,447 |
| 2019-01-14 | Langer Robert (Director) | Option Ex | 7,500 | .15 | 1,125 |
| 2018-07-20 | Symonds Jonathan (Director) | Buy | 25,000 | 23.00 | 575,000 |
| 2018-07-20 | Pomerantz Roger (Director) | Buy | 100 | 23.00 | 2,300 |
| 2018-07-20 | Sohn Catherine A. (Director) | Buy | 2,500 | 23.00 | 57,500 |
| 2018-07-20 | Cuss Francis M (Director) | Buy | 10,000 | 23.00 | 230,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of RUBY listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rubius Therapeutics, Inc. (symbol RUBY, CIK number 1709401) see the Securities and Exchange Commission (SEC) website.